Protocol I4T-MD-JVBB(a)- A Randomized, Double-Blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy with Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
1. Patients must have progressed radiographically within 6 months of completing first line therapy, progressed radiographically 6 months after last dose of first line therapy, or discontinued part or all of first line therapy and have progressed within 6 months following.
2. Patient cannot have received any other combination of chemotherapy besides bevacizumab, oxaliplatin, and a fluoropyrimidine.
3. KRAS status must be known prior to enrollment